ChromaDex Corp (NAS:CDXC)

$ 7.72 0.08 (1.05%) Market Cap: 589.68 Mil Enterprise Value: 560.33 Mil PE Ratio: 772.00 PB Ratio: 17.08 GF Score: 75/100

Q3 2024 Chromadex Corp Earnings Call Transcript
Oct 31, 2024

$3.49 (-2.51%)

Earnings
Q2 2024 Chromadex Corp Earnings Call Transcript
Aug 07, 2024

$2.63 (-6.74%)

Earnings
Q1 2024 Chromadex Corp Earnings Call Transcript
May 08, 2024

$3.83 (+2.13%)

Earnings
Q4 2023 Chromadex Corp Earnings Call Transcript
Mar 06, 2024

$1.74 (+0.58%)

Earnings
Q3 2023 Chromadex Corp Earnings Call Transcript
Nov 08, 2023

$1.6 (+4.58%)

Earnings
Q2 2023 Chromadex Corp Earnings Call Transcript
Aug 09, 2023

$1.65 (-0.60%)

Earnings
Chromadex Corp at LD Micro Invitational Conference Transcript
Jun 06, 2023
Q1 2023 Chromadex Corp Earnings Call Transcript
May 10, 2023

$1.47 (+6.14%)

Earnings
Q4 2022 Chromadex Corp Earnings Call Transcript
Mar 08, 2023

$1.83 (+12.96%)

Earnings
Q3 2022 Chromadex Corp Earnings Call Transcript
Nov 02, 2022

$1.67 (+1.83%)

Earnings
Q2 2022 Chromadex Corp Earnings Call Transcript
Aug 10, 2022

$2.06 (+7.29%)

Earnings
Chromadex Corp KOL Webinar on the Transforming Benefits of Nicotinamide Riboside (NR) Transcript
Jul 20, 2022
Q1 2022 Chromadex Corp Earnings Call Transcript
May 12, 2022

$1.64 (+0.61%)

Earnings
Q4 2021 Chromadex Corp Earnings Call Transcript
Mar 09, 2022

$2.72 (+4.62%)

Earnings
Q3 2021 Chromadex Corp Earnings Call Transcript
Nov 03, 2021

$6.55 (+2.18%)

Earnings
Q2 2021 Chromadex Corp Earnings Call Transcript
Aug 03, 2021

$8.73 (-2.13%)

Earnings
Q1 2021 Chromadex Corp Earnings Call Transcript
May 06, 2021

$8.58 (-3.92%)

Earnings
Q4 2020 Chromadex Corp Earnings Call Transcript
Mar 10, 2021

$10.75 (-6.20%)

Earnings
Q3 2020 Chromadex Corp Earnings Call Transcript
Nov 04, 2020

$4.78 (+1.49%)

Earnings
Q2 2020 Chromadex Corp Earnings Call Transcript
Aug 06, 2020

$4.92 (-4.28%)

Earnings
Q1 2020 Chromadex Corp Earnings Call Transcript
May 11, 2020

$5.46

Earnings
Q4 2019 Chromadex Corp Earnings Call Transcript
Mar 10, 2020

$3.43 (-2.28%)

Earnings
Q3 2019 Chromadex Corp Earnings Call Transcript
Nov 12, 2019

$2.83 (-0.70%)

Earnings
Q2 2019 Chromadex Corp Earnings Call Transcript
Aug 07, 2019

$4.37 (-2.24%)

Earnings
Q1 2019 Chromadex Corp Earnings Call Transcript
May 09, 2019

$4.74 (+1.94%)

Earnings
Q4 2018 Chromadex Corp Earnings Call Transcript
Mar 07, 2019

$3.43 (-1.44%)

Earnings

Chromadex Corp KOL Webinar on the Transforming Benefits of Nicotinamide Riboside (NR) Transcript

Jul 20, 2022 / 03:00PM GMT

Release Date Price: $1.92 (+13.61%)

Transcript

Tara Sobierajski

Good morning, and welcome to the ChromaDex KOL Webinar. (Operator Instructions) This call is being recorded and a replay will be made available on the ChromaDex website following the conclusion of the event. I'd now like to turn the call over to your host, Robert Fried, Chief Executive Officer of ChromaDex. Please go ahead, Robert.

Robert N. Fried

ChromaDex Corporation - CEO & Director

Thank you so much. Good morning, everyone, and thank you for joining us on today's KOL webinar on the transformational benefits of nicotinamide riboside, also referred to as NR or Niagen for short.

For those of you whom I've not had the pleasure of meeting, it's nice to meet you. My name is Rob Fried, and I'm the CEO of ChromaDex. ChromaDex is the leading bioscience company dedicated to healthy aging and research on the many benefits of nicotinamide riboside, which is by far the most efficient precursor to nicotinamide adenine dinucleotide or NAD.

NAD is the mission-critical coenzyme to cellular metabolism and declines naturally as we age.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.